Pretax income is the income that a company earns before paying income taxes. Histogen's pretax income for the
three
months ended in Sep. 2023 was $-3.85 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.38 Mil.
Histogen's pretax margin was -77,080.00%.
During the past 4 years, Histogen's highest Pretax Margin was -26.55%. The lowest was -65178.95%. And the median was -598.15%.
Histogen Pre-Tax Income Historical Data
The historical data trend for Histogen's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Histogen's Pre-Tax Income
For the Biotechnology subindustry, Histogen's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Histogen's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Histogen's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Histogen's Pre-Tax Income falls into.
Histogen Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Histogen's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Histogen (OTCPK:HSTO) Pre-Tax Income Explanation
Histogen's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as
During the past 4 years, Histogen's highest Pretax Margin was -26.55%. The lowest was -65178.95%. And the median was -598.15%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Histogen Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Histogen's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSTO has been successfully added to your 